drugset / Trial / NCT03768063
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study
NaParallel-groupOpen-labelTreatment
Summary
This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.
Timeline
- Start
- 2019-02-28
- Primary completion
- 2028-07-05
- Completion
- 2028-07-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alectinib | Small molecule | — | — |
| Subject | Atezolizumab | Monoclonal antibody | 1200 mg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Cabozantinib | Small molecule | — | — |
| Subject | Cobimetinib | Small molecule | — | — |
| Subject | Emactuzumab | Monoclonal antibody | — | — |
| Subject | Enzalutamide | Other / unclassified | — | — |
| Subject | Niraparib | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Comparator | Pembrolizumab | Monoclonal antibody | — | — |
| Subject | Pemetrexed | Small molecule | — | — |
| Subject | Rucaparib | Small molecule | — | — |
| Comparator | Sunitinib | Small molecule | — | — |
| Subject | Vemurafenib | Small molecule | — | — |
| Subject | Venetoclax | Small molecule | — | — |
| Subject | simlukafusp alfa | Protein / enzyme biologic | — | — |